Validea Joel Greenblatt Strategy Daily Upgrade Report

Validea's Earnings Yield Investor model, based on Joel Greenblatt's strategy, upgraded CureVac BV (CVAC) from a 0% to a 90% rating, indicating strong interest due to the firm's fundamentals and valuation, while Harmony Biosciences Holdings Inc (HRMY) was upgraded from 70% to 80%, suggesting some interest, though it ultimately failed the final ranking. Greenblatt's value model focuses on companies with high return on capital and earnings yields, and his "Magic Formula" achieved back-tested returns of 30.8 percent per year from 1988 through 2004.

Analysis

Validea's Earnings Yield Investor model, which employs Joel Greenblatt's value investing strategy focused on high return on capital and earnings yields, has upgraded CureVac BV (CVAC), a small-cap biotechnology firm, from a 0% to a 90% rating. This significant upgrade indicates strong model interest, attributed to the firm's underlying fundamentals and valuation, and aligns with a high per-ticker sentiment score of 0.8. Despite its Earnings Yield and Return on Tangible Capital being categorized as "NEUTRAL" by the model's specific criteria, CVAC ultimately received a "PASS" on its final ranking. CVAC is a clinical-stage company developing mRNA-based medicines and collaborates with GSK. Concurrently, Harmony Biosciences Holdings Inc (HRMY), another small-cap biotechnology stock, was upgraded from a 70% to an 80% rating by the same model, suggesting some strategic interest based on its fundamentals and valuation. However, HRMY, which also showed "NEUTRAL" for Earnings Yield and Return on Tangible Capital, received a "FAIL" in its final ranking according to Greenblatt's criteria, a finding that corresponds with a negative per-ticker sentiment of -0.3. This discrepancy for HRMY highlights that not all criteria are equally weighted and the final ranking encapsulates a broader assessment. The overall market sentiment for this news is moderately positive, though the direct market impact score is low.

Key Decisions for Investors

• Investors may find CureVac BV (CVAC) an interesting prospect under a Greenblatt-style value strategy given its 90% model rating and 'PASS' status, although the 'NEUTRAL' scores on individual metrics warrant further due diligence into its specific fundamental strengths.
• For Harmony Biosciences Holdings Inc (HRMY), caution is advised; while the model's interest score increased to 80%, the 'FAIL' in the final ranking and negative ticker sentiment suggest underlying issues that need thorough investigation before considering an investment.
• Consider that both companies presented 'NEUTRAL' on key Greenblatt metrics, yet achieved different final outcomes, underscoring the importance of understanding the holistic application of the 'Magic Formula' rather than relying solely on isolated component scores.